| Company Name | Exchange | Ticker | Last Price | Total Analyst Coverage |
Upgrade/ Downgrade |
Analyst Name | Rating Company | Target Price |
Upside/ Downside (%) |
|---|---|---|---|---|---|---|---|---|---|
| Platinum Group Metals Ltd | TSX | PTM | 1.12 | 617.5 | Upgrade to buy/neutral from neutral/neutral | Eugene King | Goldman Sachs | 2.00 | 78.6% |
| SEMAFO Inc | TSX | SMF | 3.47 | 957.9 | Initiate with market perform | Mike Kozak | Cormark Securities Inc. | 4.00 | 15.3% |
| Lorus Therapeutics Inc | TSX | LOR | 0.46 | 54.7 | Initiate with outperform | Adnan Butt | RBC Capital Markets | 2.00 | 334.8% |
| Concordia Healthcare Corp | TSX | CXR | 31.38 | 748.8 | Initiate with buy | Martin Landry | GMP | 36.00 | 14.7% |
| Brookfield Residential Properties Inc | TSX | BRP | 22.85 | 2,719.9 | Downgrade to sector perform from outperform | Robert C Wetenhall Jr | RBC Capital Markets | 24.97 | 9.3% |
Goldman Sachs upgraded Platinum Group Metals Ltd (TSX: PTM), a platinum focused exploration and development company conducting work on staked or acquired mineral properties, to buy/neutral from neutral/neutral increasing its price target to C$2.00 from C$1.30, indicating an upside of 78.6% from current levels.
Cormark Securities Inc. initiated coverage on SEMAFO Inc (TSX: SMF), a Canadian-based mining company with gold production and exploration activities, with a market perform rating assigning a 12-month price target of C$4.00, indicating an upside of 15.3% from current levels.
Coverage on Lorus Therapeutics Inc (TSX: LOR), a life sciences company focused on the discovery, research and development of effective anticancer therapies with a safety profile, was initiated with an outperform rating at RBC Capital Markets with a 12-month price target of C$2.00, indicating an upside of 334.8% from current levels.
GMP initiated coverage on Concordia Healthcare Corp (TSX: CXR), an integrated, specialty healthcare company focused on the acquisition of pharmaceutical products and medical devices and the acquisition and/or development of orphan drugs, with a buy rating assigning a 12-month price target of C$36.00, indicating an upside of 14.7% from current levels.
RBC Capital Markets downgraded Brookfield Residential Properties Inc (TSX: BRP), a land developer and homebuilder, to sector perform from outperform lowering its price target to C$24.97 from C$25.04, indicating an upside of 9.3% from current levels.
| Company Name | Exchange | Ticker | Last Price |
Total Analyst Coverage |
Upgrade/ Downgrade |
Analyst Name | Rating Company | Target Price |
Upside/ Downside (%) |
|---|---|---|---|---|---|---|---|---|---|
| The Pantry Inc | NASDAQ | PTRY | 16.17 | 379.2 | Upgrade to outperform from neutral | Dane Leone | Macquarie | 29.00 | 79.3% |
| The Andersons Inc | NASDAQ | ANDE | 50.94 | 1,436.5 | Upgrade to outperform from market perform | Kenneth B Zaslow | BMO Capital Markets | 56.00 | 9.9% |
| MercadoLibre Inc | NASDAQ | MELI | 82.10 | 3,625.0 | Upgrade to overweight from neutral | Andre Baggio | JPMorgan | 104.00 | 26.7% |
| Oppenheimer Holdings Inc | NYSE | OPY | 24.08 | 325.4 | Initiate with buy | Hugh M Miller | Sidoti & Company LLC | 34.00 | 41.2% |
| Manchester United Plc | NYSE | MANU | 16.19 | 2,652.1 | Downgrade to neutral from overweight | Mark O’Donnell | JPMorgan | 17.50 | 8.1% |
Macquarie upgraded The Pantry Inc (NASDAQ: PTRY), an independently operated convenience store chain offering a range of merchandise, fuel and ancillary products and services, to outperform from neutral increasing its price target to $29.00 from $14.00, indicating an upside of 79.3% from current levels. The rating firm believes that under the scenario where the assets are redistributed into an effective dealer network, the value of the PTRY’s asset base could be much higher than current valuation. Moreover, analyst Dane Leone believes that the recent changes to the board of directors may act a catalyst for the company to grow.
The Andersons Inc (NASDAQ: ANDE), a diversified company engaged in agriculture business, was upgraded to outperform from market perform at BMO Capital Markets increasing its price target to $56.00 from $55.00, indicating an upside of 9.9% from current levels. The rating firm upgraded the stock on attractive fundamentals of the company.
JPMorgan upgraded MercadoLibre Inc (NASDAQ: MELI), an Argentina-based company active in the e-commerce industry, to overweight from neutral with a price target of $104.00, indicating an upside of 26.7% from current levels.
However, JP Morgan downgraded Manchester United Plc (NYSE: MANU), engaged in the operations of professional sports team, to neutral from overweight lowering its price target to $17.50 from $18.90, indicating an upside of 8.1% from current levels.
Sidoti & Company LLC initiated coverage on Oppenheimer Holdings Inc (NYSE: OPY), a middle-market investment bank and service broker-dealer, with a buy rating assigning a 12-month price target of $34.00, indicating an upside of 41.2% from current levels.
.
